Goldman Sachs
VOR icon

Goldman Sachs’s Vor Biopharma VOR Stock Holding History

Goldman Sachs’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.67M Buy
261,891
+116,251
+80% +$1.64M ﹤0.01% 3773
2025
Q4 		$1.9M Buy
145,640
+129,854
+823% +$2.42M ﹤0.01% 4636
2025
Q3 		$769K Buy
15,786
+6,747
+75% +$271K ﹤0.01% 5224
2025
Q2 		$293K Buy
9,039
+4,792
+113% +$42.3K ﹤0.01% 5453
2025
Q1 		$60.9K Buy
4,247
+2,912
+218% +$69.9K ﹤0.01% 5863
2024
Q4 		$29.6K Sell
1,335
-76
-5% -$1.26K ﹤0.01% 5873
2024
Q3 		$19.8K Sell
1,411
-17,356
-92% -$316K ﹤0.01% 5674
2024
Q2 		$375K Buy
18,767
+14,108
+303% +$456K ﹤0.01% 4983
2024
Q1 		$221K Buy
4,659
+2,742
+143% +$120K ﹤0.01% 5083
2023
Q4 		$86.3K Buy
1,917
+639
+50% +$26.4K ﹤0.01% 5317
2023
Q3 		$54.2K Sell
1,278
-811
-39% -$44K ﹤0.01% 5270
2023
Q2 		$129K Sell
2,089
-2,575
-55% -$235K ﹤0.01% 5311
2023
Q1 		$502K Buy
+4,664
New +$517K ﹤0.01% 4822
2022
Q4 		– Sell
-953
Closed -$76K – 6287
2022
Q3 		$76K Sell
953
-424
-31% -$41.7K ﹤0.01% 5741
2022
Q2 		$137K Buy
1,377
+97
+8% +$9.93K ﹤0.01% 5763
2022
Q1 		$155K Buy
1,280
+418
+48% +$71.2K ﹤0.01% 5967
2021
Q4 		$200K Buy
+862
New +$249K ﹤0.01% 5903

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs's VOR Position: Q1 2026 in Review

Goldman Sachs increased its Vor Biopharma (VOR) stake by 80% in Q1 2026, buying an estimated $1.64M and bringing the position to 261,891 shares worth $4.67M. The position accounts for ﹤0.01% of the portfolio, ranked #3773.

Goldman Sachs first reported a position in VOR in Q4 2021 and has held it in 17 quarters since. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Goldman Sachs held 261,891 shares of Vor Biopharma worth $4.67M as of Q1 2026.
  • Goldman Sachs bought 116,251 Vor Biopharma shares in Q1 2026, an estimated $1.64M.
  • Vor Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3773 holding.
  • Goldman Sachs first reported a position in Vor Biopharma in Q4 2021 and has held it in 17 quarters since.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.